Business Context and Reporting Period
Company: Eli Lilly and Company (LLY)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Lilly operates as a single segment focused on the discovery, development, manufacturing, and marketing of human pharmaceutical products. The company's portfolio is heavily concentrated in cardiometabolic health, oncology, immunology, and neuroscience. In 2025, the company continued significant manufacturing expansion to meet demand for its incretin medicines (Mounjaro and Zepbound) and announced preliminary voluntary agreements with the U.S. government regarding drug pricing and access.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $65,179 | $45,043 | +45% |
| Net Income | $20,640 | $10,590 | +95% |
| Diluted EPS | $22.95 | $11.71 | +96% |
| Gross Margin | $54,127 | $36,625 | +48% |
| Gross Margin % | 83.0% | 81.3% | +1.7 pts |
| Operating Cash Flow | $16,813 | $8,818 | +91% |
| Capital Expenditures | $7,841 | $5,058 | +55% |
| Total Debt | $42,503 | $33,644 | +26% |
| Cash & Equivalents | $7,268 | $3,268 | +122% |
Revenue Drivers: Revenue growth was driven primarily by volume increases in Mounjaro and Zepbound, which collectively accounted for 56% of total revenue in 2025. This volume growth was partially offset by lower realized prices.
Material Changes vs. Prior Period
- Revenue Surge: Consolidated revenue increased 45% year-over-year, with U.S. revenue up 43% and non-U.S. revenue up 48%. Mounjaro revenue grew 99% and Zepbound revenue grew 175% compared to 2024.
- Profitability Expansion: Net income nearly doubled (95% increase) due to higher gross margins driven by favorable product mix and improved production costs, despite increased operating expenses.
- Expense Growth: Research and development (R&D) expenses rose 21% to $13.3 billion, and marketing, selling, and administrative (MSA) expenses rose 29% to $11.1 billion to support product launches and pipeline development.
- Debt and Liquidity: Total debt increased by $8.9 billion to $42.5 billion, primarily due to new long-term debt issuances in 2025 to fund business development and general purposes. Cash and cash equivalents more than doubled to $7.3 billion.
- Acquisitions: The company recognized $2.9 billion in acquired in-process research and development (IPR&D) charges, primarily related to the acquisitions of Scorpion Therapeutics and SiteOne Therapeutics.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Management Commentary
Management expects cardiometabolic health products to remain a significant and growing portion of the business. Near-term financial performance is expected to be impacted by the timing of regulatory approvals for orforglipron and the expansion of U.S. Medicare access for Zepbound. The company is undertaking significant manufacturing expansion, with additional capacity expected to come online over the next several years.
Key Risks and Contingencies
- Pricing and Reimbursement: The company faces significant pressure from the Inflation Reduction Act (IRA), which allows government-set prices for certain drugs. Jardiance is subject to price setting in 2026, and Trulicity and Verzenio were selected for price setting effective in 2028. Lilly also announced preliminary voluntary agreements with the U.S. government to lower Medicaid prices and launch new medicines with balanced pricing.
- Supply Chain and Manufacturing: The company relies on third-party suppliers, including those in China, creating exposure to geopolitical tensions and tariffs. Manufacturing capacity expansion is critical to meeting demand for high-volume products.
- Intellectual Property: Loss of patent protection for key products (e.g., Trulicity) poses a risk of rapid revenue decline due to generic or biosimilar competition.
- Legal Proceedings: Significant litigation includes insulin pricing lawsuits, 340B program disputes, and product liability claims related to incretin medicines (Mounjaro, Trulicity, Zepbound). The company is predominantly self-insured for litigation liability.
Unusual Items
The company recognized a $484 million charge for asset impairment, restructuring, and other special charges in 2025, primarily related to litigation and acquisition integration costs. Additionally, the company repurchased $4.1 billion of shares in 2025 under a $15.0 billion program authorized in December 2024.
Investor Verification Checklist
- Product Concentration: Verify the sustainability of revenue growth given that Mounjaro and Zepbound accounted for 56% of total revenue in 2025.
- IRA Impact: Assess the financial impact of government-set pricing on Jardiance (2026) and Trulicity/Verzenio (2028) as outlined in the Inflation Reduction Act.
- Manufacturing Capacity: Monitor the timeline and success of manufacturing expansion initiatives to ensure supply meets demand for incretin medicines.
- Legal Exposure: Review the status of insulin pricing litigation and 340B program disputes, as adverse outcomes could materially affect results.
- Debt Levels: Evaluate the increase in total debt to $42.5 billion and the company's ability to service this debt while maintaining high capital expenditure levels.